Company
Sydney, NSW
Every investor coverage indicates participated in a round Promethean BioPharma raised.
Companies Promethean BioPharma acquired or merged with, per published coverage. Buying a company is not investing in one: nothing here counts in the deals column.
| Name | Role | Sources |
|---|---|---|
| Peter Comerford | Chief Executive Officer | Dealroom |
Stories naming Promethean BioPharma. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Sydney biotech Promethean BioPharma has launched an OnMarket crowdfunding round to fund manufacturing, trials and its push for non-prescription status of its CBD pain tablet in Australia.